Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3TR-ABC severe asthma biologic response cohort
NL-OMON52133Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of dupilumab, mepolizumab, benralizumab, tezepelumab, omalizumab and 1 more in asthma (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Baseline biomarkers of remission after 1 year of biologic therapy, eNose/VOC multi-omics phenotyping to predict treatment response and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON52133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52133.